Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients

Table 1

Baseline clinical characteristics of the study population (n = 33).

Age (years)	52.6 ± 9.8
BMI (kg/m^2)	21.4 ± 3.6
CTx (ng/mL)	0.62 ± 0.10
Serum calcium (mg/dL)	9.1 ± 0.7
Serum phosphorous (mg/dL)	3.4 ± 0.5
25-Hydroxyvitamin D (ng/mL)	30.3 ± 10.0
Type of malignancy, n (%)
Acute myeloid leukemia	11 (33.3)
Acute lymphoid leukemia	14 (42.4)
Myelodysplastic syndrome	8 (24.3)
Baseline BMD (g/cm^2)
Lumbar spine	0.923 ± 0.143
Femur neck	0.723 ± 0.093
Total hip	0.728 ± 0.105
Steroid exposure, n (%)	22 (66.7%)

Continuous variables are presented as mean ± standard variation; categorical variables are presented as number (percentage); CTx, cross-linked C-terminal telopeptide of type 1 collagen; BMD, bone mineral density. Serum calcium level is adjusted calcium for albumin.